Palbociclib
Brand name: Ibrance
Palbociclib comes in 15 pill versions in our database, in 3 strengths, from 4 manufacturers. Check the imprint to tell them apart.
Palbociclib pill images
75 mg 5 pills
- PBC 75 Pfizer Palbociclib 75 mg Orange, capsule, 18 mm Used for breast cancer
- Pfizer PBC 75 Palbociclib 75 mg Purple, round, 10 mm Used for breast cancer
- No picture yet DIN 02493535 Palbociclib 75 mg Ibrance, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02547635 Palbociclib 75 mg Taro-Palbociclib, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02552124 Palbociclib 75 mg PMS-Palbociclib, Tablet, sold in Canada Used for breast cancer
100 mg 5 pills
- PBC 100 Pfizer Palbociclib 100 mg Brown & orange, capsule, 20 mm Used for breast cancer
- Pfizer PBC 100 Palbociclib 100 mg Green, oval, 15 mm Used for breast cancer
- No picture yet DIN 02493543 Palbociclib 100 mg Ibrance, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02547643 Palbociclib 100 mg Taro-Palbociclib, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02552132 Palbociclib 100 mg PMS-Palbociclib, Tablet, sold in Canada Used for breast cancer
125 mg 5 pills
- PBC 125 Pfizer Palbociclib 125 mg Brown, capsule, 22 mm Used for breast cancer
- Pfizer PBC 125 Palbociclib 125 mg Purple, oval, 16 mm Used for breast cancer
- No picture yet DIN 02493551 Palbociclib 125 mg Ibrance, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02547651 Palbociclib 125 mg Taro-Palbociclib, Tablet, sold in Canada Used for breast cancer
- No picture yet DIN 02552140 Palbociclib 125 mg PMS-Palbociclib, Tablet, sold in Canada Used for breast cancer
What is Palbociclib used for?
Palbociclib is used for breast cancer.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
HER2-Negative Metastatic Breast Cancer
IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- an aromatase inhibitor as initial endocrine-based therapy; or
- fulvestrant in patients with disease progression following endocrine therapy.
IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy.
HER2-Positive Metastatic Breast Cancer
IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
From the FDA-approved label on DailyMed (published Jul 09, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.